In3Bio is an innovation driven biotech company with a broad R&D platform of novel therapeutics that offer potential treatment for multiple cancers

Our Story

In3Bio is a privately held biotechnology company based in the UK. Established in 2010, In3Bio’s innovation-driven program is dedicated to new therapeutics that can provide cancer patients new and effective treatments with emphasis on tolerability.

We have built a broad R&D platform that offer potential treatment for multiple indications of cancer, both as mono therapy and in combination with other treatments.

INVENT

Create or design (something that has not existed before) ; be the originator of

INVEST

Devote one’s time, effort and energy to a particular undertaking with the expectation of a worthwhile result

INNOVATE

Make changes in something established, especially by introducing new methods, ideas, or products

We are committed to therapeutic improvement in the area of immuno-oncology, with a dedicated effort to invent, invest and innovate.

In3Bio’s diversified novel therapeutics are projected to enter into the clinic in 2020.

01

Programme under phase 1

02

Pipeline in CMO

04

Pipeline in advance development

08

Cancer target and more

15

Targeted drugs tested in combination with our pipelines

Novel Therapeutics

We primarily focus on pathway target immunisation (PTI), by stimulating the patient’s immune system to fight cancer. Using our immunisation approach, we have been able to develop new therapeutic options that are effective and tolerable in combination with existing treatments.

In3Bio has established collaborations with several leading academic institutions in Europe and works with Key Opinion Leaders. Our new therapeutics are without the heavy toxicity associated with standard treatment. This situates us in a competitive edge, allowing to provide a robust and versatile product pipeline.

In3Bio Team

Our commitment for creating meaningful treatment for patients is what sets us apart. We focus not only on survival benefit but also on a better quality of life. To learn more about the incredible In3Bio team, please have a look below.

Tan Sri Dato' Dr. Abu Bakar Suleiman

Chairman

Abu Bakar became chairman of the group in 2009. He is a fellow of the Royal Australasian College of Physicians and completed his post-graduate training in Nephrology at Georgetown, University Hospital, Washington DC and Prince Henry’s Hospital in Melbourne between 1975 and1976. He attended the Advanced Management Programme at Harvard Business School in 1991 and became Director General of Health Malaysia from 1991 to 2001, before being appointed President of IMU in 2001 and Chairman of IHH Berhad in 2011.

Tan Sri Abu Bakar was the President, Malaysia Medical Association (1985), Master, Academy of Medicine Malaysia (1990-1998), Founding President, Malaysian Society of Nephrology, Founding President, Malaysian Society of Transplantation, President, Malaysian Health Informatics Information, President, Board of Governors, National Kidney Foundation, President, National Diabetes Institute, President, Association of Private Hospitals, Malaysia

Abu Bakar’s experience covers both public and private healthcare.

Johan Indot

Executive Deputy Chairman and founder

Johan is the founder and major shareholder of the group (incorporated in 2002) He is an entrepreneur and his first business was a direct selling company that was eventually sold to a PLC. He is currently chairman of his family investment company that owns a finance business for motor vehicles. He has interest in oil and gas as well as a mobile solutions software company and serves on the board of these companies.

Johan assumed a full-time executive role in 2006, the position of Deputy Executive Chairman in 2017 and leads the management team.

Dr Erik D’Hondt

Chief Scientific Officer / Head of regulatory Affairs

Erik joined the group in 2009 as Head of R&D and Regulatory Affairs. Erik is a highly experienced drug development executive who worked for 28 years at SmithKline Beechams (now GlaxoSmithKline) in biologics research and regulatory roles. He has expertise in vaccine development from bench to market and has prepared almost a dozen different viral vaccines at GSK.

More recently Erik was Vice President of Therapeutics at Europe’s Innogenetics (now Fujibio Europe) and he has consulted widely in Asia for institutes and biotech companies.

Erik was an advisor to WHO HQ Geneva on the Project: Preparedness of Asia for Pandemic Influenza at the time of the Flu H1N1 bird Influenza, 2006/2007.

Erik leads the R&D and regulatory activities at In3Bio. He has experience in managing two global Phase III clinical trials including approvals from the MHRA, PEI and FDA.

Thomas Thevenet

Head - Clinical Development

Thomas joined In3Bio in 2018 as Head of Clinical Development. He is a clinician with more than 15 years of experience in clinical development in immunology, oncology, infectious diseases and vaccines.

He is trained and knowledgeable in clinical study methodology and GXPs, as well as data management, biostatistics and regulatory affairs. After working for the Hospices Civils de Lyon Hospital, France, and the French National Institute of Health, he worked as a clinical development leader for several companies including Sanofi and Novartis. More recently, he was Clinical Development Manager and Biometrics Director at Advanced Accelerator Applications, a Novartis company.

Thomas holds a PhD in Pharmacy from the French University of Lyon and a Special Degree in Industrial and Biomedical Pharmacy from the same university.

Dr Lesley Pillans

Medical Liaison & Eudravigilence

Lesley is a Special Grade Doctor in Eating Disorders and practices in Aberdeen, Scotland. She had worked as Medical Advisor for Shell International BV at the Hague. She also worked in Malaysia as Clinical Research Officer at University Malaya Medical Centre in Kuala Lumpur.

Lesley Joined the group in 2012 and is the medical advisor to the Board

Shirley Chong

Financial Controller

Shirley started her career as Tax Consultant with KPMG Tax Services Sdn Bhd for 6 years. She is a Chartered Accountant, member of Malaysian Institute of Accountants. She left KPMG in 2006 to join commercial industry in Finance & Accounts.

She joined Bioven in 2016 as Financial Controller and is based in the KL office.

Partnership

We seek partnership for combined treatments with approved therapies and to address the limitations faced in Immuno-Oncology

The collaboration approach will :

Reduce the development costs
Identify potential commercial partners

With our R&D platform established through partnerships with academic and pharmaceutical companies, we are interested in partnerships that can offer :

Design and evaluation of combination strategies
Out-license opportunities for clinical development and commercialisation